Antibe Therapeutics Inc. (TSXV:ATE) announced today that following the
receipt of a No Objection Letter from Health Canada last week, its Phase
I clinical trial was initiated today. This first clinical study of
ATB-346, a drug with the promise of being a safer, anti-inflammatory
painkiller, involves safety and pharmacokinetic evaluations in healthy
human subjects and will be conducted in Montreal, Canada over the coming
Dan Legault, Antibe's CEO, said, "We are extremely excited to have
initiated this study. We wish to thank our development partners for
their commitment to ATB-346. Their efforts in working so closely with
our team enabled this study to be initiated rigt after receiving
approval from Health Canada. We look forward to continuing ATB-346's
rapid and rigorous clinical development."
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and
inflammation. These medicines are based on Nobel Prize-winning medical
research highlighting the crucial role of gaseous mediators, chemical
substances produced in the human body, to regulate a range of
fundamental cellular processes. The company's drug design approach
involves chemically linking an existing off-patent drug to an
Antibe-patented, hydrogen sulfide-releasing molecule. For medical
conditions characterized by inflammation or pain, this approach can
efficiently produce improved versions of existing drugs.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
[ Back To NFVZone's Homepage ]